Magmaris Magnesium BRS: safety and performance of an advanced and innovative technology
16 May 2017 – From EuroPCR 2017
Consult this session presented by M. Joner, W. Wijns and M.K.Y. Lee if you want to find out more about the best indication for patient selection in 2017, ultrathin, bioresorbable polymer sirolimus-eluting stents vs thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisatio; the new update on Dual Antiplatelet Therapy (DAPT) VALIDATE-SWEDEHEART, TROPICAL-ACS and RE-DUAL PCI from the ESC 2017 and more...
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial
06 Sep 2017
2017 ESC Focused update on Dual Antiplatelet Therapy (DAPT)
04 Sep 2017
As dual antiplatelet therapy (DAPT) seems to have been interventionalists’ close companion since the pioneering studies showing its benefits over oral anticoagulants (OAC) some 20 years ago, the myriad of ensuing studies has led to expanding indications, but has also uncovered the inherent risks of DAPT. In the 2017 Focused Update, the hitherto accumulated evidence is eloquently summarized into a set of recommendations that provide guidance on some of the important questions of an interventional cardiologist's everyday practice: which of the currently available P2Y12 inhibitors should be selected, what is the optimal duration of DAPT and how to manage bleeding complications.
New ESC Guidelines on Acute Myocardial Infarction in patients presenting with ST-segment elevation (STEMI)
30 Aug 2017
Within the four guidelines released at the ESC Congress 2017, the STEMI guidelines may probably represent one of the most interesting for our community. Many of the changes in recommendations were already expected by many of us, whereas others are important to see and to digest.
VALIDATE-SWEDEHEART, TROPICAL-ACS and RE-DUAL PCI: Antithrombotic Therapy takes the stage
In the accompanying editorial of COMPASS, presented at the ESC Congress 2017 in Barcelona, Eugene Braunwald vividly referred to the field of “Thrombocardiology”. Indeed, the topic of antithrombotic pharmacotherapy is now broader than ever, with plenty of drugs, indications, strategies and clinical data. Three new trials (with simultaneous publications in the New England Journal of Medicine and in The Lancet) clarify doubts, inform clinical practice and open new questions.
Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?
Better stents, IVUS, FFR, medical therapy…or the integration of all? The SYNTAX-II trial
27 Aug 2017
Marking 40 years of angioplasty - EuroIntervention at the centre of interventional cardiology!
EuroIntervention at the centre of interventional cardiology! Consult the latest edition of EuroIntervention Journal - marking 40 years of angioplasty.
Bifurcation stenting, when do I need two stents?
18 Aug 2017 - From EUROPCR 2017
Treating bifurcation lesions is a challenge, and the need to convert to a two-stent strategies can be daunting. Join experts G. G. Toth, T. Johnson and F. Mangiacapra as they discuss their own insights and suggestions, reminding us to never forget the provisional approach. What percentage of cases might necessitate converting to a two-stent technique? What elements in anatomy, lesion or the type of patient might require this change? Which two-stent strategy should you begin with – and practice? What imaging tools are useful and what possible role does functional assessment play? Watch video and find out…
Late stent migration in thoracic endovascular aortic repair: a potentially lethal complication - Image 22
Author: Nelson Vale, Portugal